source
- Biohaven's ataxia drug resubmission accepted by FDA, shares surge 36%Biohaven’s experimental drug troriluzole, being developed for spinocerebellar ataxia, was previously rejected by the FDA because the agency questioned the design of the registrational trial. The co…
- Biotech sector logs 31 IPOs in 2026, with four more slated, still far below 2021 boomBiotech IPO activity has accelerated this year, with 31 companies completing public offerings so far, according to BioSpace data. This figure exceeds the totals from each of the previous four year…